Orphazyme A/S

Orphazyme A/Sverified

ORPH

Price:

$0.87

Market Cap:

$25.14M

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

Industry

Biotechnology

IPO Date

2020-09-04

Stock Exchange

NASDAQ

Ticker

ORPH

The Enterprise Value as of March 2026 (TTM) for Orphazyme A/S (ORPH) is 21.25M

According to Orphazyme A/S’s latest financial reports and current stock price. The company's current Enterprise Value is 21.25M. This represents a change of -3.60% compared to the average of 22.05M of the last 4 quarters.

Orphazyme A/S (ORPH) Historical Enterprise Value (quarterly & annually)

How has ORPH Enterprise Value performed in the past?

The mean historical Enterprise Value of Orphazyme A/S over the last ten years is 554.92M. The current 21.25M Enterprise Value has changed 283.01% with respect to the historical average. Over the past ten years (40 quarters), ORPH's Enterprise Value was at its highest in in the June 2020 quarter at 1.74B. The Enterprise Value was at its lowest in in the December 2014 quarter at -51823500.00.

Quarterly (TTM)
Annual

Average

554.92M

Median

513.85M

Minimum

-7881280.00

Maximum

1.40B

Orphazyme A/S (ORPH) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Orphazyme A/S Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 185.65%

Maximum Annual Enterprise Value = 1.40B

Minimum Annual Increase = -1065.33%

Minimum Annual Enterprise Value = -7881280.00

Quarterly (TTM)
Annual
YearEnterprise ValueChange
202426.75M-24.19%
202335.28M-547.66%
2022-7881280.00-101.47%
2021537.01M-56.94%
20201.25B-11.02%
20191.40B185.65%
2018490.68M66.88%
2017294.03M-61.93%
2016772.41M2.69%
2015752.14M-1065.33%

Orphazyme A/S (ORPH) Average Enterprise Value

How has ORPH Enterprise Value performed in the past?

The current Enterprise Value of Orphazyme A/S (ORPH) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

18.05M

5-year avg

367.66M

10-year avg

554.92M

Orphazyme A/S (ORPH) Enterprise Value vs. Peers

How is ORPH’s Enterprise Value compared to its peers?

Orphazyme A/S’s Enterprise Value is greater than Eyenovia, Inc. (18.53M), greater than Satsuma Pharmaceuticals, Inc. (20.18M), greater than Lumos Pharma, Inc. (3.04M), greater than LianBio (-36424187.00), less than Lunai Bioworks Inc. (35.18M), greater than Marinus Pharmaceuticals, Inc. (20.16M), less than Cerecor Inc. (22.77M), less than Pluristem Therapeutics Inc. (43.01M), greater than Magenta Therapeutics, Inc. (-7259976.00), less than GreenLight Biosciences Holdings (57.81M),

Build a custom stock screener for Orphazyme A/S (ORPH) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Orphazyme A/S using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Orphazyme A/S (ORPH) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Orphazyme A/S or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Orphazyme A/S's Enterprise Value?

What is the highest Enterprise Value for Orphazyme A/S (ORPH)?

What is the 3-year average Enterprise Value for Orphazyme A/S (ORPH)?

What is the 5-year average Enterprise Value for Orphazyme A/S (ORPH)?

How does the current Enterprise Value for Orphazyme A/S (ORPH) compare to its historical average?